Patents Assigned to ZymoGenetics
  • Antibodies to cytokine receptor zalpha11
    Patent number: 7638286
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: December 29, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Darrell C. Conklin, Julia E. Novak, Angela K. Hammond
  • Human cytokine receptor
    Patent number: 7638602
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: July 24, 2007
    Date of Patent: December 29, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Methods of treating pain and inflammation in neuronal tissue using antagonists of IL-31, IL31Ra and/or OSMRb
    Patent number: 7638126
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: January 10, 2007
    Date of Patent: December 29, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Polynucleotide encoding an IL-28A polypeptide
    Patent number: 7638305
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 29, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
    Patent number: 7635767
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: December 22, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • METHOD FOR TREATING CERVICAL CANCER
    Publication number: 20090311215
    Abstract: Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus. IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 17, 2009
    Applicant: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
  • Polynucleotide encoding an IL-28A polypepide
    Patent number: 7629149
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 8, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Polynucleotide encoding an IL-28B polypeptide
    Patent number: 7629148
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 8, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Polynucleotides encoding soluble zalpha11 cytokine receptors
    Patent number: 7629452
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: December 8, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R. Presnell, Richard D. Holly, Andrew J. Nelson
  • Isolated nucleic acid sequence comprising SEQ ID NO: 14 and methods of using said nucleic acid sequence
    Patent number: 7629445
    Abstract: The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: December 8, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Susan D. Holderman, Chung Chan
  • Cytokine zalpha11 ligand antibodies
    Patent number: 7626002
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: December 1, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Method of treating inflammation using soluble IL-17RCX4
    Patent number: 7622116
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: November 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Rolf E. Kuestner, Zeren Gao, Steven D. Levin, Mark W. Rixon
  • IL-21 production in prokaryotic hosts
    Patent number: 7622561
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: November 24, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Bruce L. Zamost, Hong Y. Liu, Karen S. De Jongh
  • Antibodies that bind interleukin-17 receptor homologue
    Patent number: 7619071
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: November 17, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder
  • Methods of detecting cancer with antibodies to cytokine receptor ZCYTOR19
    Patent number: 7618791
    Abstract: Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: November 17, 2009
    Assignee: ZymoGenetics, LLC
    Inventor: Theodore E. Whitmore
  • MATERIALS AND METHODS FOR PREPARING DIMERIC GROWTH FACTORS
    Publication number: 20090280562
    Abstract: Proteins consisting of, from amino to carboxyl terminus, a first PDGF-D growth factor domain polypeptide, a linker polypeptide, and a second PDGF-D growth factor domain polypeptide, and materials and methods for making the proteins are disclosed. Each of the first and second PDGF-D growth factor domain polypeptides consists of a sequence of amino acid residues as shown in SEQ ID NO:2 or SEQ ID NO:4 from amino acid x to amino acid y, wherein x is an integer from 246 to 258, inclusive, and y is an integer from 365-370, inclusive. The linker polypeptide consists of from 11-40 amino acid residues. The proteins can be used to stimulate the production of bone and/or connective tissue in both humans and non-human animals.
    Type: Application
    Filed: June 29, 2009
    Publication date: November 12, 2009
    Applicant: Zymogenetics, Inc.
    Inventors: Brian A. Fox, Margaret Dow Moore, Kristine M. Swiderek, Carl W. Birks
  • Human cytokine receptor
    Patent number: 7615611
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: November 10, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • LEVELS OF BLyS/APRIL HETEROTRIMERS IN SERUM AND USE IN DIAGNOSTIC METHODS
    Publication number: 20090274711
    Abstract: The present invention provides a method of measuring the levels of BLyS/APRIL heterotrimers (HT) in a biological sample, in a preferred embodiment, in serum. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with HT antagonists, either singly or in combination with other immune suppressive drugs.
    Type: Application
    Filed: April 22, 2009
    Publication date: November 5, 2009
    Applicant: ZymoGenetics, Inc.
    Inventors: Stacey R. Dillon, Brandon J. Harder
  • Methods of using cytokine zalpha11 ligand
    Patent number: 7611699
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: November 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Polynucleotides encoding interleukin-17 receptor homologue
    Patent number: 7612191
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: November 3, 2009
    Assignee: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Steven K. Burkhead, Sarah L. Pownder